The 2009 Import and Export Market for Glycosides, Glands or Other Organs and Extracts, Antisera, Vaccines, and Similar Products in Africa
ICON Group International, May 2009, Pages: 47
On the demand side, exporters and strategic planners approaching the market in Africa face a number of questions. Which countries are supplying glycosides, glands or other organs and extracts, antisera, vaccines, and similar products to Africa? What is the dollar value of these imports? How much do the imports of glycosides, glands or other organs and extracts, antisera, vaccines, and similar products vary from one country to another in Africa? Do exporters serving the market in Africa have similar market shares across the importing countries? On the supply side, Africa also sells to the international market of glycosides, glands or other organs and extracts, antisera, vaccines, and similar products. Which countries in Africa supply the most exports of glycosides, glands or other organs and extracts, antisera, vaccines, and similar products? Which countries are buying their exports? What is the value of these exports and which countries are the largest buyers?
This report was created for strategic planners, international marketing executives and import/export managers who are concerned with the market for glycosides, glands or other organs and extracts, antisera, vaccines, and similar products in Africa. With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics that appear several years after the fact. I have developed a methodology, based on macroeconomic and trade models, to estimate the market for glycosides, glands or other organs and extracts, antisera, vaccines, and similar products for those countries serving Africa via exports or supplying from Africa via imports. We do so for the current year based on a variety of key historical indicators and econometric models.
In what follows, Chapter 2 begins by summarizing where Africa fits into the world market for imported and exported glycosides, glands or other organs and extracts, antisera, vaccines, and similar products. The total level of imports and exports on a worldwide basis, and those for Africa in particular, is based on a model which aggregates across over 150 key country markets and projects these to the current year. From there, each country represents a percent of the world market. This market is served from a number of competitive countries of origin. Based on both demand- and supply-side dynamics, market shares by country of origin are then calculated across each country market destination. These shares lead to a volume of import and export values for each country and are aggregated to regional and world totals. In doing so, we are able to obtain maximum likelihood estimates of both the value of each market and the shares that countries in Africa are likely to receive this year. From these figures, rankings are calculated to allow managers to prioritize markets within Africa. In this way, all the figures provided in this report are forecasts that can be combined with internal information for strategic planning purposes.
After the worldwide summary in Chapter 2 of both imports and exports for Africa, Chapter 3 details the exports of glycosides, glands or other organs and extracts, antisera, vaccines, and similar products, but for each individual country in Africa. Chapter 4 does the same, but for imports of glycosides, glands or other organs and extracts, antisera, vaccines, and similar products for all countries in Africa. In all cases, the total dollar volume and percentage share values by major trading partner are provided. Combined, Chapters 3 and 4 present the complete picture for imports and exports of glycosides, glands or other organs and extracts, antisera, vaccines, and similar products to and from Africa to and from all other countries in the world. Of the 150 countries considered, if a country is not reported here it is therefore estimated to have only a negligible level of trade in glycosides, glands or other organs and extracts, antisera, vaccines, and similar products (i.e. their market shares are close or equal to zero percent). "Glycosides, Glands or Other Organs and Extracts, Antisera, Vaccines, and Similar Products" as a category is defined in this report following the definition given by the United Nations Statistics Division Classification Registry using the Standard International Trade Classification, Revision 3 (SITC, Rev. 3). The SITC code that defined "glycosides, glands or other organs and extracts, antisera, vaccines, and similar products" is 5416 . For more information on this definition, please refer to the following web site:
http://unstats.un.org/unsd/cr/registry/regcs.asp?Cl=14&Lg=1&Co=541 .
1 METHODOLOGY 7
1.1 Our Approach 7
2 AFRICA’S SHARE OF THE WORLD MARKET 10
2.1 Exports from Africa as Share of the World Export Market 10
2.2 Imports in Africa as Share of the World Import Market 12
3 EXPORTS FROM AFRICA 16
3.1 Executive Summary 16
3.2 Algeria 18
3.3 Botswana 18
3.4 Cameroon 19
3.5 Egypt 19
3.6 Kenya 19
3.7 Morocco 20
3.8 Senegal 20
3.9 South Africa 21
3.10 St. Helena 22
3.11 Tanzania 22
3.12 Tunisia 22
3.13 Zambia 22
3.14 Zimbabwe 23
4 IMPORTS INTO AFRICA 24
4.1 Executive Summary 24
4.2 Algeria 28
4.3 Benin 29
4.4 Burkina Faso 29
4.5 Burundi 30
4.6 Cameroon 30
4.7 Cape Verde 31
4.8 Egypt 32
4.9 Gabon 33
4.10 Ghana 33
4.11 Kenya 34
4.12 Madagascar 35
4.13 Malawi 35
4.14 Mauritius 36
4.15 Morocco 37
4.16 Senegal 38
4.17 South Africa 39
4.18 Sudan 40
4.19 Tanzania 41
4.20 the Gambia 41
4.21 Togo 42
4.22 Tunisia 43
4.23 Uganda 44
4.24 Zambia 44
4.25 Zimbabwe 45
5 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS 46
5.1 Disclaimers & Safe Harbor 46
5.2 ICON Group Ltd. User Agreement Provisions 47
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
